Brain chromatin remodeling: a novel mechanism of alcoholism.
The treatment of alcoholism requires the proper management of ethanol withdrawal symptoms, such as anxiety, to prevent further alcohol use and abuse. In this study, we investigated the potential role of brain chromatin remodeling, caused by histone modifications, in alcoholism. We found that the anxiolytic effects produced by acute alcohol were associated with a decrease in histone deacetylase (HDAC) activity and increases in acetylation of histones (H3 and H4), levels of CREB (cAMP-responsive element binding) binding protein (CBP), and neuropeptide Y (NPY) expression in the amygdaloid brain regions of rats. However, the anxiety-like behaviors during withdrawal after chronic alcohol exposure were associated with an increase in HDAC activity and decreases in acetylation of H3 and H4, and levels of both CBP and NPY in the amygdala. Blocking the observed increase in HDAC activity during alcohol withdrawal with the HDAC inhibitor, trichostatin A, rescued the deficits in H3 and H4 acetylation and NPY expression (mRNA and protein levels) in the amygdala (central and medial nucleus of amygdala) and prevented the development of alcohol withdrawal-related anxiety in rats as measured by the elevated plus maze and light/dark box exploration tests. These results reveal a novel role for amygdaloid chromatin remodeling in the process of alcohol addiction and further suggest that HDAC inhibitors may be potential therapeutic agents in treating alcohol withdrawal symptoms.
Pandey
Subhash C
SC
Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois 60612, USA. scpandey@uic.edu
Ugale
Rajesh
R
Zhang
Huaibo
H
Tang
Lei
L
Prakash
Anand
A
D000437:Alcoholism / Q000473:pathology*; D000818:Animals; D001522:Behavior, Animal; D001921:Brain / Q000503:physiopathology*; D002492:Central Nervous System Depressants / Q000008:administration & dosage; D042002:Chromatin Assembly and Disassembly / Q000187:drug effects / Q000502:physiology*; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D000431:Ethanol / Q000008:administration & dosage; D005106:Exploratory Behavior / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D051548:Histone Acetyltransferases / Q000378:metabolism; D006655:Histone Deacetylases / Q000378:metabolism; D006877:Hydroxamic Acids / Q000008:administration & dosage; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D009478:Neuropeptide Y / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome
D002492:Central Nervous System Depressants; D017362:Cyclic AMP Response Element-Binding Protein; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D009478:Neuropeptide Y; D000431:Ethanol; C012589:trichostatin A; D051548:Histone Acetyltransferases; D006655:Histone Deacetylases